Arcadia Biosciences (RKDA) Competitors

Arcadia Biosciences logo
$0.19 0.00 (-2.01%)
As of 04:00 PM Eastern

RKDA vs. KO, KOF, PEP, MNST, and CCEP

Should you buy Arcadia Biosciences stock or one of its competitors? Arcadia Biosciences's main competitors and comparable companies include Coca-Cola (KO), Coca Cola FEMSA (KOF), PepsiCo (PEP), Monster Beverage (MNST), and Coca-Cola Europacific Partners (CCEP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "soft drinks & non-alcoholic beverages" industry.

How does Arcadia Biosciences compare to Coca-Cola?

Arcadia Biosciences (NASDAQ:RKDA) and Coca-Cola (NYSE:KO) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Coca-Cola has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Coca-Cola, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.75M0.10-$2.34M-$4.89N/A
Coca-Cola$47.94B8.93$13.11B$3.4029.27

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 70.3% of Coca-Cola shares are held by institutional investors. 4.5% of Arcadia Biosciences shares are held by company insiders. Comparatively, 0.9% of Coca-Cola shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arcadia Biosciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Coca-Cola has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

In the previous week, Coca-Cola had 53 more articles in the media than Arcadia Biosciences. MarketBeat recorded 57 mentions for Coca-Cola and 4 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.45 beat Coca-Cola's score of 0.65 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcadia Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Coca-Cola
22 Very Positive mention(s)
13 Positive mention(s)
5 Neutral mention(s)
7 Negative mention(s)
2 Very Negative mention(s)
Positive

Coca-Cola has a net margin of 28.65% compared to Arcadia Biosciences' net margin of -202.09%. Coca-Cola's return on equity of 38.79% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-202.09% -200.22% -86.32%
Coca-Cola 28.65%38.79%13.50%

Coca-Cola has a consensus price target of $97.26, suggesting a potential downside of 2.27%. Given Coca-Cola's stronger consensus rating and higher probable upside, analysts clearly believe Coca-Cola is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Coca-Cola
0 Sell rating(s)
3 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.92

Summary

Coca-Cola beats Arcadia Biosciences on 14 of the 17 factors compared between the two stocks.

How does Arcadia Biosciences compare to Coca Cola FEMSA?

Coca Cola FEMSA (NYSE:KOF) and Arcadia Biosciences (NASDAQ:RKDA) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Coca Cola FEMSA currently has a consensus target price of $121.43, suggesting a potential upside of 0.72%. Given Coca Cola FEMSA's stronger consensus rating and higher probable upside, analysts clearly believe Coca Cola FEMSA is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coca Cola FEMSA
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.67
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

17.7% of Arcadia Biosciences shares are owned by institutional investors. 1.0% of Coca Cola FEMSA shares are owned by company insiders. Comparatively, 4.5% of Arcadia Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Arcadia Biosciences had 1 more articles in the media than Coca Cola FEMSA. MarketBeat recorded 4 mentions for Arcadia Biosciences and 3 mentions for Coca Cola FEMSA. Arcadia Biosciences' average media sentiment score of 1.45 beat Coca Cola FEMSA's score of 0.23 indicating that Arcadia Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coca Cola FEMSA
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcadia Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Coca Cola FEMSA has a net margin of 7.95% compared to Arcadia Biosciences' net margin of -202.09%. Coca Cola FEMSA's return on equity of 15.76% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Coca Cola FEMSA7.95% 15.76% 7.27%
Arcadia Biosciences -202.09%-200.22%-86.32%

Coca Cola FEMSA has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

Coca Cola FEMSA has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Coca Cola FEMSA, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coca Cola FEMSA$15.22B13.32$1.32B$6.5518.41
Arcadia Biosciences$4.75M0.10-$2.34M-$4.89N/A

Summary

Coca Cola FEMSA beats Arcadia Biosciences on 12 of the 17 factors compared between the two stocks.

How does Arcadia Biosciences compare to PepsiCo?

Arcadia Biosciences (NASDAQ:RKDA) and PepsiCo (NASDAQ:PEP) are both consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

PepsiCo has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than PepsiCo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.75M0.10-$2.34M-$4.89N/A
PepsiCo$93.93B2.12$8.24B$7.9618.40

PepsiCo has a consensus price target of $142.94, indicating a potential downside of 2.38%. Given PepsiCo's stronger consensus rating and higher probable upside, analysts clearly believe PepsiCo is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
PepsiCo
2 Sell rating(s)
13 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.20

Arcadia Biosciences has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, PepsiCo has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, PepsiCo had 36 more articles in the media than Arcadia Biosciences. MarketBeat recorded 40 mentions for PepsiCo and 4 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.45 beat PepsiCo's score of 0.51 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcadia Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PepsiCo
16 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
7 Negative mention(s)
3 Very Negative mention(s)
Positive

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 73.1% of PepsiCo shares are held by institutional investors. 4.5% of Arcadia Biosciences shares are held by company insiders. Comparatively, 0.1% of PepsiCo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PepsiCo has a net margin of 11.09% compared to Arcadia Biosciences' net margin of -202.09%. PepsiCo's return on equity of 53.08% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-202.09% -200.22% -86.32%
PepsiCo 11.09%53.08%10.42%

Summary

PepsiCo beats Arcadia Biosciences on 14 of the 17 factors compared between the two stocks.

How does Arcadia Biosciences compare to Monster Beverage?

Monster Beverage (NASDAQ:MNST) and Arcadia Biosciences (NASDAQ:RKDA) are both consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

72.4% of Monster Beverage shares are owned by institutional investors. Comparatively, 17.7% of Arcadia Biosciences shares are owned by institutional investors. 8.1% of Monster Beverage shares are owned by insiders. Comparatively, 4.5% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Monster Beverage has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Monster Beverage presently has a consensus price target of $67.07, indicating a potential upside of 46.44%. Given Monster Beverage's stronger consensus rating and higher probable upside, research analysts clearly believe Monster Beverage is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monster Beverage
0 Sell rating(s)
9 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.63
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Monster Beverage had 14 more articles in the media than Arcadia Biosciences. MarketBeat recorded 18 mentions for Monster Beverage and 4 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.45 beat Monster Beverage's score of 1.01 indicating that Arcadia Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monster Beverage
9 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcadia Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Monster Beverage has a net margin of 22.66% compared to Arcadia Biosciences' net margin of -202.09%. Monster Beverage's return on equity of 24.99% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Monster Beverage22.66% 24.99% 20.49%
Arcadia Biosciences -202.09%-200.22%-86.32%

Monster Beverage has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Monster Beverage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monster Beverage$8.29B10.81$1.91B$1.1041.64
Arcadia Biosciences$4.75M0.10-$2.34M-$4.89N/A

Summary

Monster Beverage beats Arcadia Biosciences on 14 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Coca-Cola Europacific Partners?

Arcadia Biosciences (NASDAQ:RKDA) and Coca-Cola Europacific Partners (NASDAQ:CCEP) are both consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

In the previous week, Coca-Cola Europacific Partners had 3 more articles in the media than Arcadia Biosciences. MarketBeat recorded 7 mentions for Coca-Cola Europacific Partners and 4 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.45 beat Coca-Cola Europacific Partners' score of 0.69 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcadia Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Coca-Cola Europacific Partners
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Coca-Cola Europacific Partners has a consensus price target of $110.33, suggesting a potential downside of 7.43%. Given Coca-Cola Europacific Partners' stronger consensus rating and higher probable upside, analysts clearly believe Coca-Cola Europacific Partners is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Coca-Cola Europacific Partners
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58

Coca-Cola Europacific Partners has higher revenue and earnings than Arcadia Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.75M0.10-$2.34M-$4.89N/A
Coca-Cola Europacific Partners$23.64B2.32$2.20BN/AN/A

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 31.4% of Coca-Cola Europacific Partners shares are owned by institutional investors. 4.5% of Arcadia Biosciences shares are owned by company insiders. Comparatively, 3.0% of Coca-Cola Europacific Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Coca-Cola Europacific Partners has a net margin of 0.00% compared to Arcadia Biosciences' net margin of -202.09%. Coca-Cola Europacific Partners' return on equity of 0.00% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-202.09% -200.22% -86.32%
Coca-Cola Europacific Partners N/A N/A N/A

Arcadia Biosciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Coca-Cola Europacific Partners has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

Coca-Cola Europacific Partners beats Arcadia Biosciences on 12 of the 15 factors compared between the two stocks.

Get Arcadia Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RKDA vs. The Competition

MetricArcadia BiosciencesBeverages IndustryConsumer Staples SectorNASDAQ Exchange
Market Cap$457K$24.60B$17.42B$11.66B
Dividend YieldN/A2.56%3.23%4.42%
P/E Ratio-0.0426.9625.3929.85
Price / Sales0.102.451.785.62
Price / Cash0.1718.4516.4522.50
Price / Book0.083.533.213.66
Net Income-$2.34M$905.79M$844.95M$392.27M
7 Day Performance14.97%0.78%-0.90%-4.72%
1 Month Performance15.11%5.57%-0.07%-7.14%
1 Year Performance-94.91%-0.23%-2.34%-7.51%

Arcadia Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RKDA
Arcadia Biosciences
1.0685 of 5 stars
$0.19
-2.0%
N/A-94.9%$457K$4.75MN/A8
KO
Coca-Cola
3.8044 of 5 stars
$97.59
+0.7%
$97.26
-0.3%
+39.9%$416.90B$47.94B29.1965,900
KOF
Coca Cola FEMSA
4.201 of 5 stars
$120.96
+0.7%
$121.43
+0.4%
+37.2%$201.90B$15.22B18.34108,840
PEP
PepsiCo
4.1237 of 5 stars
$143.94
+0.2%
$143.28
-0.5%
+0.4%$195.70B$93.93B17.08306,000
MNST
Monster Beverage
3.7192 of 5 stars
$45.40
+0.1%
$67.07
+47.7%
+28.5%$88.75B$8.29B39.606,891

Related Companies and Tools


This page (NASDAQ:RKDA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners